NCT04590599 2023-12-18A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based ChemotherapyInnovent Biologics (Suzhou) Co. Ltd.Phase 2 Completed205 enrolled